Clinical Trial

Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases

Study acronym: NeurOmics
Recruiting
View on ClinicalTrials.gov →
Summary
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expression (transcriptomic and epigenomic), protein and metabolic data and clinical data, the study also aims to identify new markers for the diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases. The study involves the enrolment of at least 1.200 individuals with neurodegenerative disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-14.
Trial Details
NCT Number NCT07235111
Lead Sponsor Ospedale Policlinico San Martino
Collaborators: Istituto Italiano di Tecnologia
Conditions Alzheimer Disease, FTD, Young-onset Dementia, MCI, Parkinson Disease, ALS (Amyotrophic Lateral Sclerosis)
Enrollment 1,200 participants
Start Date 2025-02-28
Primary Completion 2034-09-17 (estimated)
Study Completion 2039-09-17 (estimated)
Updated on ClinicalTrials.gov 2025-11-25